IsoRay (ISR) Reports Q3 Loss of $0.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
IsoRay Announces Third Quarter Fiscal 2016 Financial Results and Early Conclusions from Ongoing Strategic Review Process
May 10, 2016 4:07 PM EDTRICHLAND, Wash., May 10, 2016 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced its financial results for the third quarter and nine months of fiscal 2016, ended March 31, 2016.
Revenue was $1.2 million for the third quarter of fiscal 2016, ended March 31, 2016, a 3.5% increase compared to $1.16 million for the third quarter of fiscal 2015, ended March 31, 2015. Prostate brachytherapy represented 87% and 86%... More
